Values First Advisors Inc. Acquires 476 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Values First Advisors Inc. raised its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 7.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,983 shares of the biopharmaceutical company’s stock after acquiring an additional 476 shares during the period. Values First Advisors Inc.’s holdings in Alnylam Pharmaceuticals were worth $1,337,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ALNY. Harbor Capital Advisors Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 1.8% during the fourth quarter. Harbor Capital Advisors Inc. now owns 2,938 shares of the biopharmaceutical company’s stock valued at $562,000 after purchasing an additional 51 shares in the last quarter. Captrust Financial Advisors boosted its stake in shares of Alnylam Pharmaceuticals by 4.3% during the second quarter. Captrust Financial Advisors now owns 1,285 shares of the biopharmaceutical company’s stock valued at $187,000 after purchasing an additional 53 shares in the last quarter. EP Wealth Advisors LLC boosted its stake in shares of Alnylam Pharmaceuticals by 6.4% during the third quarter. EP Wealth Advisors LLC now owns 1,177 shares of the biopharmaceutical company’s stock valued at $208,000 after purchasing an additional 71 shares in the last quarter. CIBC Asset Management Inc boosted its stake in shares of Alnylam Pharmaceuticals by 2.0% during the first quarter. CIBC Asset Management Inc now owns 4,191 shares of the biopharmaceutical company’s stock valued at $840,000 after purchasing an additional 84 shares in the last quarter. Finally, Oppenheimer & Co. Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 2.1% during the third quarter. Oppenheimer & Co. Inc. now owns 4,519 shares of the biopharmaceutical company’s stock valued at $800,000 after purchasing an additional 93 shares in the last quarter. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Trading Down 3.2 %

Alnylam Pharmaceuticals stock traded down $4.94 during trading on Friday, hitting $149.45. 666,592 shares of the company were exchanged, compared to its average volume of 702,111. Alnylam Pharmaceuticals, Inc. has a 52 week low of $143.52 and a 52 week high of $218.88. The business’s 50 day moving average is $160.27 and its 200 day moving average is $170.47.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, February 15th. The biopharmaceutical company reported ($1.10) EPS for the quarter, topping the consensus estimate of ($1.20) by $0.10. The company had revenue of $439.72 million during the quarter, compared to the consensus estimate of $439.38 million. During the same period in the prior year, the firm posted ($1.68) EPS. The business’s revenue was up 31.2% on a year-over-year basis. On average, sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -4.61 earnings per share for the current fiscal year.

Analyst Ratings Changes

ALNY has been the topic of a number of recent analyst reports. Morgan Stanley cut their price objective on Alnylam Pharmaceuticals from $184.00 to $176.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 13th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $165.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Tuesday, February 20th. Citigroup cut their price objective on Alnylam Pharmaceuticals from $237.00 to $227.00 and set a “buy” rating on the stock in a research note on Friday, February 16th. Wolfe Research started coverage on Alnylam Pharmaceuticals in a research note on Thursday, February 15th. They issued a “peer perform” rating on the stock. Finally, Chardan Capital dropped their price target on Alnylam Pharmaceuticals from $250.00 to $225.00 and set a “buy” rating on the stock in a research note on Friday, February 16th. Eight research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $216.12.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.